Skip to main content
SpringerLink
Log in

NICE issues erlotinib guidance for use in NSCLC

  • Media release
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. National Institute for Health and Clinical Excellence (NICE).NICE issues guidance on the use of erlotinib for the treatment of non-small-cell lung cancer. Media Release: 25 Nov 2008. Available from: URL: http://www.nice.org.uk

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

NICE issues erlotinib guidance for use in NSCLC. Pharmacoecon. Outcomes News 568, 3 (2008). https://doi.org/10.2165/00151234-200805680-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00151234-200805680-00006

Keywords

Search

Navigation